LBO-004 Final results of MYR301: a randomised phase 3 study evaluating the efficacy and safety of up to 144 weeks of bulevirtide monotherapy for chronic hepatitis delta and 96 weeks of posttreatment follow-up

IF 26.8 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2025-05-01 DOI:10.1016/S0168-8278(25)00313-7

Heiner Wedemeyer, Soo Aleman, Antje Blank, Pietro Andreone, Pavel Bogomolov, Vladimir Chulanov, Nina Mamonova, Natalia Geyvandova, Viacheslav Morozov, Olga Sagalova, Tatiana Stepanova, Annemarie Berger, Sandra Ciesek, Amos Lichtman, Dmitry Manuilov, Renee-Claude Mercier, Sarah Arterburn, Florence Christian-Cox, Steve Tseng, Anu Osinusi, Pietro Lampertico

引用次数: 0

查看原文本刊更多论文

LBO-004: MYR301的最终结果：一项随机3期研究，评估长达144周的布来韦肽单药治疗慢性丁型肝炎和96周治疗后随访的有效性和安全性

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.